ImmunoCellular plummets on ICT-107 Phase II miss

ImmunoCellular Therapeutics tried to put a positive spin on statistically significant progression-free survival (PFS) for newly-diagnosed glioblastoma multiforme patients treated with the dendritic cell-based cancer vaccine ICT-107 in a Phase II clinical trial, but the company's stock dropped by more than half based on the trial's missed overall survival (OS) primary endpoint.

ImmunoCellular Therapeutics tried to put a positive spin on statistically significant progression-free survival (PFS) for newly-diagnosed glioblastoma multiforme patients treated with the dendritic cell-based cancer vaccine ICT-107 in a Phase II clinical trial, but the company's stock dropped by more than half based on the trial's missed overall survival (OS) primary endpoint.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.